Skip to main content
. 2016 Oct 28;7(48):79761–79773. doi: 10.18632/oncotarget.12962

Figure 1. Therapeutic effects of VOSL and its main active ingredients on liver cancer.

Figure 1

A. A flow diagram of VOSL isolation and identification of its active ingredients using a bioactivity-oriented screening platform. B. Cell lines were exposed to Cos, Dehy, C+2D and VOSL for 48 h. Cell viability was measured by MTT assay and the IC50 value of the tested samples was calculated using the Trimmed Spearman-Karber Method. C. SMMC-7721 cells were injected subcutaneously into the axillary fossa of nude mice until the tumors reached about 2-3 mm in diameter. The mice were treated with Cos, Dehy, C+2D, VOSL and 5-FU at the indicated concentrations, n=6 in every group. Tumor volume was measured and compared; **p < 0.01 and ***p < 0.001 compared with the negative control (NT) group. D and E. The tumors were harvested and weighed after 24 times of administrations; *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the NT group.